Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13180243 | 0.87 | RIOK2 (0.60) | RIOK2PKMJAK2TYK2MEN1 | |
| SCHEMBL15350436 | 0.87 | LOXL2 (0.61) | RIOK2PKMJAK2JAK1TYK2 | |
| SCHEMBL13415578 | 0.87 | RIOK2 (0.60) | RIOK2PKMMEN1KMT2ANR3C2 | |
| SCHEMBL91333 | 0.85 | RIOK2 (0.57) | RIOK2PKMJAK2JAK1TYK2 | |
| SCHEMBL25985837 | 0.84 | RIOK2 (0.57) | RIOK2PKMMEN1KMT2ANR3C2 | |
| SCHEMBL14273251 | 0.83 | BRAF (0.61) | RIOK2PKMJAK2JAK1TYK2 | |
| SCHEMBL13180241 | 0.82 | PKM (0.64) | RIOK2PKMMEN1KMT2ANR3C2 | |
| SCHEMBL20988697 | 0.82 | RIOK2 (0.54) | RIOK2PKMJAK2JAK1TYK2 | |
| SCHEMBL631091 | 0.81 | JAK2 (0.68) | JAK2JAK1TYK2MEN1KMT2A | |
| SCHEMBL16311114 | 0.81 | JAK2 (0.53) | RIOK2PKMJAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | RIOK2 1336/4885PKM 2117/4885JAK2 67/4885 |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | RIOK2 1447/4885PKM 1790/4885JAK2 109/4885 |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | RIOK2 1164/4885PKM 1752/4885JAK2 83/4885 |
| US-20110213003-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC3 | RIOK2 1394/4885PKM 2285/4885JAK2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.